This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genentech Purchases Arrayit Technology

Stocks in this article: ARYC

SUNNYVALE, Calif., Sept. 10, 2013 /PRNewswire/ --  Arrayit Corporation (OTCQB: ARYC) reports that pharmaceutical giant Genentech has purchased Arrayit's patented technology to accelerate drug discovery.

Genentech purchased Arrayit's NanoPrint™ LM60 Microarrayer Platform including a manufacturing robot, printing pins and consumables for $138,000. Genentech's pioneering research using ARYC technology was published in the April 2013 edition of "Current Protocols in Protein Science" by Genentech scientists Dr. Irene Tom, Dr. Nicholas Lewin‐Koh, Dr. Sree R. Ramani and Dr. Lino C. Gonzalez in the Department of Protein Chemistry, Genentech, in South San Francisco, California USA. The scientific publication is available on-line using the link: http://www.currentprotocols.com/WileyCDA/CPUnit/refId-ps2703.html

Genentech scientists employ Arrayit protein microarray technology to screen protein-protein interactions in a massively parallel manner as a means of speeding the discovery of new protein drugs. Genentech's authors emphasize that "Functional protein microarrays offer the capability for high-throughput protein interaction analysis and have long promised to be a powerful tool for understanding protein interactions at the proteome scale."

Proteins are the molecules encoded by cellular genes, and the approximately 25,000 genes in the human genome encode all of the known proteins in the human body, which is known as the human proteome. Proteins possess significant therapeutic value, as emphasized by Genentech's blockbuster protein drugs Rituxan, Avastin and Herceptin, which have combined annual sales of approximately $7.8B. Genentech was acquired by Roche in 2009 for $46.8B and operates as a member of the Roche Group.

List of other Arrayit Corp Customers

Government Laboratories

Centers for Disease Control

Veterans Administration Medical Center

SAIC

West Point Military Academy

Sandia National Laboratory

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs